Back
ESC Premium Access

Cost-effective analysis of HOST-EXAM

Session: Latest Science in ACS
Topic: Pharmacotherapy
Speaker: Doctor H. Kim (Seoul, KR)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

0

About the speaker

Doctor Hyo-Soo Kim

Seoul National University Hospital, Seoul (Korea (Republic of))
4 presentations
0 follower

10 more presentations in this session

Colchicine in Acute Myocardial Infarction

Speaker: Professor N. Mewton (Lyon, FR)

Access
Slides
Video
0
Thumbnail

Effects of Sacubitril/valsartan compared with ramipril on coronary events after myocardial infarction - Results from the PARADISE-MI Trial

Speaker: Professor R. Mehran (New York, US)

Access
Slides
Video
0
Thumbnail

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

Speaker: Professor D. Bhatt (New York City, US)

Access
Slides
Video
0
Thumbnail

BIC-8 Revisited - Copeptin together with high sensitivity troponin for managemnent of suspected NSTE-ACS

Speaker: Assistant Professor E. Giannitsis (Heidelberg, DE)

Access
Slides
Video
0
Thumbnail

Incidence, associated outcomes and predictors of upper gastrointestinal bleeding following acute myocardial infarction - a SWEDEHEART based nationwide cohort study

Speaker: Doctor P. Sarajlic (Stockholm, SE)

Access
Slides
Video
0
Thumbnail

Access the full session

Latest Science in ACS

Speakers: Doctor H. Kim, Professor N. Mewton, Professor R. Mehran, Professor D. Bhatt, Assistant Professor E. Giannitsis...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Cardiovascular benefits outweigh risks in patients with atrial fibrillation in REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial)

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

ESC 365 is supported by

logo Novo Nordisk